Rapid Therapeutic Finalizes Lab Work on Pharmaceutical Formulas
DALLAS, June 10, 2021 (GLOBE NEWSWIRE) -- Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL), an SEC fully-reporting, growth-oriented aerosol manufacturing company focused on delivery of non-psychoactive cannabinoid compounds, announced today that it has concluded lab development on three (3) formulas related to manufacturing of pharmaceutical grade isolates used in both metered dose inhalers and other aerosol products.
RTSL has developed three (3) proprietary pharmaceutical formulas, two (2) for cannabidiol (CBD) and one (1) for cannabigerol (CBG), to initially be used in Metered Dose Inhalers (MDI). One CBD formula is expected to be used in testing of the MDI which the Company plans to submit to the U.S. Food and Drug Administration (FDA) in connection with an Investigational New Drug Application (IND), as previously announced. The other two are planned to be used in RTSL’s other products.
RTSL’s CEO, Donal R. Schmidt, Jr. stated, “We initially set out to find an ultra-pure, unadulterated pharmaceutical grade CBD isolate to use in our MDI. Early on we learned the purity level of an isolate is materially related to airway irritation and the level of cough reflex when using an MDI. We also learned CBD isolate is not chemically compatible with metered dose inhalers without significant modifications in the manufacturing process. In short, we were unsatisfied with any product we could source in the hemp space to meet our needs. As such, we set out to engineer a quality isolate to meet our needs.”
“With the purchase of Razor Jacket and the addition of Dr. Drinkwine, each as previously announced, we learned how to manufacture pharmaceutical grade isolate in-house. We believe our process is unique and will result in one or more patents being granted to RTSL. Once the patent applications have been filed, which are planned to be filed in the next few weeks, we expect to release the details of our findings, which we believe will make a significant impact in the hemp space related to isolate manufacturing.”
In conclusion, Mr. Schmidt stated, “At this point, as we head to market with other non-MDI products and while we are preparing to submit the IND, we believe we are well positioned as we have an ISO 6 certified aerosol filling lab, we are progressing well on our way to completion of our Good Manufacturing Process (GMP) certification, and we believe we have true pharmaceutical grade Active Pharmaceutical Ingredints (API).”
About Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL)
RTSL is a biopharmaceutical company that has developed a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more cannabinoid compounds. The company’s nhaler product line is manufactured in compliance with GMP.
CBD is not approved by the FDA.
We encourage all individuals to do their own research regarding cannabinoids, the use of MDI and our other products. Always consult a physician prior to using any cannabinoid product. RTSL makes no therapeutic claims regarding its products, the use of its products, or any results which can be obtained from using its products. None of our products are intended to diagnose, treat, cure, or prevent any disease. If you experience any adverse reaction of any non-psychotropic cannabinoid, stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act). Our products contain zero THC.
Visit our corporate website at www.rtslco.com.
This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov.
Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements which include, among others, the timing of the filing of patent applications, the failure to obtain patents for our products and processes, the costs associated therewith, a delay in, or the failure of, our filing of the planned IND, or the failure of the FDA to approve the IND, the outcome of studies, the planned timing of product availability, the demand for such products, and our ability to produce significant quantities of such products.
The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Conference Sessions (Full conference pass required)
Encoding Values Into a New Generation of Technology